InfuSystem Holdings Inc（INFU）财务数据INFUInfuSystem Holdings Inc

InfuSystem Holdings Inc (INFU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Patient Services revenue, accounting for 59.3% of total sales, equivalent to $19.99M. Other significant revenue streams include Device Solutions revenue and Device Solutions Lease Revenue. Understanding this composition is critical for investors evaluating how INFU navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, InfuSystem Holdings Inc maintains a gross margin of 57.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.24%, while the net margin is 8.75%. These profitability ratios, combined with a Return on Equity (ROE) of 15.03%, provide a clear picture of how effectively INFU converts its operational activities into shareholder value.

In the context of the broader market, INFU competes directly with industry leaders such as IMXI and TRBG. With a market capitalization of $261.95M, it holds a leading position in the sector. When comparing efficiency, INFU's gross margin of 57.50% stands against IMXI's 100.00% and TRBG's N/A. Such benchmarking helps identify whether InfuSystem Holdings Inc is trading at a premium or discount relative to its financial performance.

InfuSystem reported a Q2 2026 revenue of $36.93 million, a 2.6% increase year-over-year, and a net income of $3.23 million, translating to an EPS of $0.15, which is a significant improvement from $0.12 in the previous year.